Giant cubes – UFOs, "RODs", anomalies in the solar space on NASA pictures for January 5, 2014 – Video

Posted on by


Giant cubes - UFOs, "RODs", anomalies in the solar space on NASA pictures for January 5, 2014
The disappearance of the sun in space. This has happened several times in the past. We see the stars, but do not see the sun! Amazing! 1:20 Detailed analysis...

By: myunhauzen74

See the rest here:

Giant cubes - UFOs, "RODs", anomalies in the solar space on NASA pictures for January 5, 2014 - Video

NASA Television Airs Pre Launch Status Briefing for Resupply Mission to Space Station – Video

Posted on by


NASA Television Airs Pre Launch Status Briefing for Resupply Mission to Space Station
NASA TV aired a pre-launch news briefings from Wallops Flight Facility to update the status of Orbital Sciences #39; Cygnus spacecraft and Orbital #39;s mission to r...

By: NASA

View original post here:

NASA Television Airs Pre Launch Status Briefing for Resupply Mission to Space Station - Video

Foundation Medicine Extends and Expands Collaboration to …

Posted on by

Mon Jan 6, 2014 4:30pm EST

* Reuters is not responsible for the content in this press release.

Foundation Medicine Extends and Expands Collaboration to Provide Molecular Information and Genomic Profiling for Clinical Oncology Programs

Foundation Medicine today announced it has extended and expanded its ongoing collaboration with Novartis to provide molecular information and comprehensive genomic profiling analysis in support of many of Novartis clinical oncology programs. The collaboration will now extend through at least September 2016.

As the result of Foundation Medicine and Novartis pilot program established in January 2011 and an expanded three-year agreement in June 2012, Foundation Medicines comprehensive genomic profiling has generated clinically relevant data and is now regularly used in many of Novartis oncology clinical trials. This new agreement, which the companies agreed to extend and expand prior to the end of the existing term, includes committed capacity for Foundation Medicine to provide genomic profiling of patient samples from Novartis clinical trials, as well as access to Foundation Medicines molecular information and analysis services. The new three-year agreement also gives Novartis the option to extend the term for an additional two-year period. Financial terms are not being disclosed.

We are deeply committed to our relationship with Novartis and pleased with the continued growth of our collaboration, said Michael J. Pellini, M.D., president and CEO, Foundation Medicine. In addition to providing comprehensive genomic profiling for patients in Novartis clinical trials, this expanded agreement will allow Novartis to take advantage of our unique and growing database of molecular information to support the evaluation and development of Novartis oncology drug candidates, biological targets and clinical trials.

Foundation Medicine uses comprehensive, clinical grade next-generation sequencing to assess routine cancer specimens for all genes that are currently known to be somatically altered and unambiguous drivers of oncogenesis in solid tumors and hematologic malignancies, as well as many sarcomas and pediatric cancers. Novartis uses these capabilities to support its targeted therapy clinical development efforts by helping to align the genomic profile of individual patients cancer with clinical trial enrollment criteria and clinical outcome analysis.

About Foundation Medicine

Foundation Medicine (NASDAQ: FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patients unique cancer. The companys clinical assays, FoundationOneTM for solid tumors and FoundationOneTM Heme for hematologic malignancies, sarcomas and pediatric cancers, each provide a fully informative genomic profile to identify a patients individual molecular alterations and match them with relevant targeted therapies and clinical trials. Foundation Medicines molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit http://www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).

Foundation Medicine is a registered trademark, and FoundationOneTMis a trademark, of Foundation Medicine, Inc.

See original here:

Foundation Medicine Extends and Expands Collaboration to ...

UCSF and Quest Diagnostics Launch Collaboration to Advance Field of Precision Medicine

Posted on by

UC San Francisco and Quest Diagnostics, the world's leading provider of diagnostic information services, have formed a collaboration to accelerate the translation of biomedical research into advanced diagnostics in the field of precision medicine, for improved patient care, treatment and outcomes.

Initial clinical areas of focus include autism, oncology, neurology and womens health.

The collaboration, which combines the research discoveries and capabilities of UCSF with the national testing database and technical and clinical development capability of Quest Diagnostics, has an overarching aim of enabling holistic and integrated diagnostic solutions that close gaps in care or enable new clinical value.

Under the terms of the agreement, scientists will jointly research, develop and validate diagnostic innovations to solve specific clinical problems and provide actionable information to improve patient care. The organizations will focus on diagnostics to advance precision medicine, an emerging field of medical science that aims to integrate the most informative data from molecular, clinical, population and other research to create predictive, preventive and precise medical solutions for patients. Quest Diagnostics would independently develop and validate any lab-developed tests for clinical use that emerge from the collaborations research.

Researchers will utilize laboratory-based diagnostics, imaging procedures and population analysis based on Quests national Health Trends database, the largest private clinical database in the U.S., based on more than 1.5 billion patient encounters, to advance precision medicine.

The alliance is the first master agreement that UCSFs Office of Innovation, Technology and Alliances has signed with a clinical laboratory testing company and augments the universitys efforts to translate laboratory research into new therapies. The broad agreement lays the groundwork for multiple projects between the two organizations.

Advances in technology and science have identified many promising opportunities to improve outcomes through insights revealed by novel diagnostic solutions, yet fulfilling the full potential of these opportunities often hinges on translational clinical studies which validate their value, said Jay Wohlgemuth, MD, senior vice president, Science and Innovation, Quest Diagnostics. This unique collaboration between UCSF and Quest brings together the finest researchers and clinicians in the country to accelerate the development of a product pipeline of scientific discoveries as clinically valuable diagnostic solutions that enable precision medicine for improved outcomes.

The collaboration is launching with two specific projects already underway. One project involves Quests national database of molecular testing data to facilitate participation in research and development efforts related to genetic variations of autism, based on Quests CGH microarray ClariSure technology, which can help identify genetic mutations associated with autism and other developmental disorders. While there currently is no treatment for autism, a test that aids its diagnosis could help identify individuals who might be appropriate candidates for research studies that could lead to future therapies.

The second project aims to identify biomarkers to determine which children with glioma brain tumors may benefit from a drug that is currently available to treat the disease. That project will integrate molecular biomarker testing with advanced MRI imaging technologies. This project is the first phase of larger collaborative studies to develop and validate integrated care pathways, which would include laboratory diagnostics, imaging data and other clinical information to be used in the management of patients with brain cancer and neurological diseases.

UCSF has been at the forefront of the movement toward precision medicine, for which UCSF Chancellor Susan Desmond-Hellmann, MD, MPH, co-authored the initial National Academy of Sciences paper that defined the new field. That paper set the vision of harnessing the vast amounts of genetic, environmental and health data worldwide to make health care more predictive, precise and targeted.

Continued here:

UCSF and Quest Diagnostics Launch Collaboration to Advance Field of Precision Medicine

UC San Francisco and Quest Diagnostics launch collaboration to advance the field of precision medicine

Posted on by

PUBLIC RELEASE DATE:

9-Jan-2014

Contact: Kristen Bole kristen.bole@ucsf.edu 415-502-6397 University of California - San Francisco

MADISON, N.J. and SAN FRANCISCO, CA, January 9, 2014 Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and the University of California, San Francisco (UCSF), the nation's leading university focused exclusively on health, have formed a collaboration to accelerate the translation of biomedical research into advanced diagnostics in the field of precision medicine, for improved patient care, treatment and outcomes. Initial clinical areas of focus include autism, oncology, neurology and women's health.

The collaboration, which combines the research discoveries and capabilities of UCSF with the national testing database and technical and clinical development capability of Quest Diagnostics, has an overarching aim of enabling holistic and integrated diagnostic solutions that close gaps in care or enable new clinical value.

Under the terms of the agreement, scientists will jointly research, develop and validate diagnostic innovations to solve specific clinical problems and provide actionable information to improve patient care. The organizations will focus on diagnostics to advance precision medicine, an emerging field of medical science that aims to integrate the most informative data from molecular, clinical, population and other research to create predictive, preventive and precise medical solutions for patients. Quest Diagnostics would independently develop and validate any lab-developed tests for clinical use that emerge from the collaboration's research.

Researchers will utilize laboratory-based diagnostics, imaging procedures and population analysis based on Quest's national Health Trends database, the largest private clinical database in the U.S., based on more than 1.5 billion patient encounters, to advance precision medicine.

The alliance is the first master agreement that UCSF's Office of Innovation, Technology and Alliances has signed with a clinical laboratory testing company and augments the university's efforts to translate laboratory research into new therapies. The broad agreement lays the groundwork for multiple projects between the two organizations.

"Advances in technology and science have identified many promising opportunities to improve outcomes through insights revealed by novel diagnostic solutions, yet fulfilling the full potential of these opportunities often hinges on translational clinical studies which validate their value," said Jay Wohlgemuth, M.D., senior vice president, Science and Innovation, Quest Diagnostics. "This unique collaboration between UCSF and Quest brings together the finest researchers and clinicians in the country to accelerate the development of a 'product pipeline' of scientific discoveries as clinically valuable diagnostic solutions that enable precision medicine for improved outcomes."

The collaboration is launching with two specific projects already underway. One project involves Quest's national database of molecular testing data to facilitate participation in research and development efforts related to genetic variations of autism, based on Quest's CGH microarray ClariSure technology, which can help identify genetic mutations associated with autism and other developmental disorders. While there currently is no treatment for autism, a test that aids its diagnosis could help identify individuals who might be appropriate candidates for research studies that could lead to future therapies.

More:

UC San Francisco and Quest Diagnostics launch collaboration to advance the field of precision medicine

Why You Should Upload Yourself to a Supercomputer

Posted on by

S

We're still decades if not centuries away from being able to transfer a mind to a supercomputer. It's a fantastic future prospect that makes some people incredibly squeamish. But there are considerable benefits to living a digital life. Here's why you should seriously consider uploading.

As I've pointed out before, uploading is not a given; there are many conceptual, technological, ethical, and security issues to overcome. But for the purposes of this Explainer, we're going to assume that uploads, or digital mind transfers, will eventually be possible whether it be from the scanning and mapping of a brain, serial brain sectioning, brain imaging, or some unknown process.

Indeed, it's a prospect that's worth talking about. Many credible scientists, philosophers, and futurists believe there's nothing inherently intractable about the process. The human brain an apparent substrate independent Turing Machine adheres to the laws of physics in a material universe. Eventually, we'll be able to create a model of it using non-biological stuff and even convert, or transfer, existing analog brains to digital ones.

So, assuming you'll live long enough to see it and muster up the courage to make the paradigmatic leap from meatspace to cyberspace here's what you have to look forward to:

Once you're living as a stream of 1's and 0's you'll never have to worry about body odor, going to the bathroom, or having to brush your teeth. You won't need to sleep or have sex unless, of course, you program yourself such that you'll both want and need to do these things (call it a purist aesthetic choice).

S

At the same time, you won't have to worry about rising cholesterol levels, age-related disorders, and broken bones. But you will have to worry about viruses (though they'll be of a radically different sort), hackers, and unhindered access to processing power.

The end of an organic, biological human life will offer the potential for an indefinitely long one. For many, virtual immortality will be the primary appeal of uploading. So long as the supercomputer in which you reside is secure and safe (e.g. planning an exodus from the solar system when the Sun enters into its death throes), you should be able to live until the universe collapses in the Big Rip something that shouldn't happen for another 22 billion years.

I spoke to futurist John Smart about this one. He's someone who's actually encouraging the development of technologies required for brain preservation and uplift. To that end, he's the Vice President of the Brain Preservation Foundation, a not-for-profit research group working to evaluate and award a number of scanning a preservation strategies.

Read the original post:

Why You Should Upload Yourself to a Supercomputer

Column: Twitter co-founder unveils Jelly, but to whom?

Posted on by

1/8/14 business By MIKE SCHUSTER/MINYANVILLE Column: Twitter co-founder unveils Jelly, but to whom?

Photo credit: MINYANVILLE

Last April, Twitter co-founder Biz Stone hinted at a new project he and his team were working on. Keeping things clandestine at first, he asked the question on his company blog, "What is Jelly?" In the months that followed, the answer was partially revealed in tiny fragments. It was to be a question-and-answer platform with a mobile approach.

This week, Jelly was revealed to be little more than that vague description.

Specifically, Jelly allows iOS and Android users to snap and upload photos to their social networks, utilizing a crowdsourced "group mind" to answer questions about the picture. For example, someone could take a photo of an unusual animal they see on a hike, upload the picture to Jelly, and ask their followers, "What in the world is this?" The app collects these photo queries and answers posted by their friends in a timeline, letting users mark their favorite responses and share them with others within and outside their particular social network.

Full story at Minyanville.

Go here to read the rest:

Column: Twitter co-founder unveils Jelly, but to whom?

The INQUIRER Android Experiment: Episode Three

Posted on by

I CAME UP with a joke today.

Q: What will we eat if Android wins the mobile operating system war?

A: Blackberry and Apple Crumble.

I never said it was a good joke. But after the day I've had, even a lame pun is better than nothing.

Monday, 6 January

At this point, I am going to let you into a little secret. I nearly caved today. I was sitting in a room with four Windows machines, all switched off. I'd spent five hours - yes, five - trying to post an article.

During that time, I fought against devices rebooting, apps that crashed for no apparent reason but always at the crucial moment, and a cut and paste mechanism that seems to have been written by the cast of Sesame Street on ritalin.

It is safe to say that, for a journalist on a successful tech website, using Android exclusively is, while not impossible, certainly not convenient. It's a little like a holiday in North Korea. It can be done, but it probably isn't very relaxing and you might not get out of it in one piece.

I'm an advocate for Android due to its open ecosystem. But that can also be its undoing. There is often inconsistency between apps that means that they behave differently than Android design guidelines, thus reducing their capacity for intuitive use.

In addition, because many apps come from back bedroom developers, they are prone to instability. There isn't a huge community of bug testers to check every possible eventuality, and you can be sure that the one they haven't tested will be the one you end up running into and finding out about the hard way.

More:

The INQUIRER Android Experiment: Episode Three

IDrive’s solution to slow cloud backups: a drive shipping service

Posted on by

21 hours ago Jan. 9, 2014 - 10:58 AM PST

Uploading hundreds of gigabytes of data can be a slow and tedious process. Thats why cloud backup provider IDrive launched a new service Thursday that replaces that upload with the postman. IDrives new IDrive Safe offering offers small to medium businesses a way to back up their data on one of the companys hard drives, then have it shipped to a managed storage location, and get it sent back if there ever is a need to restore the entire backup.

IDrives staff also makes these drives available online on request, but the data isnt accessible 24/7. IDrives Business Development CoordinatorShane Bingham told me during an interview at CES in Las Vegas this week that the offering was more about offsite backups than about cloud storage, and he suggested that this would be a good solution for businesses that still have a lot of local data, but want some peace of mind with an extra offsite copy.

IDrive Safe is $100 per year for a one-time copy of up to 1TB of data. Businesses that need their data backed up more frequently can elect to get a new drive shipped every month for $1000 per year, and a yearly backup costs $200 per year.Bingham told me that the company employs two people just for managing drive storage, and that it can scale up to manage thousands of drives within days.

0.000000 0.000000

Subscriber Content

Subscriber content comes from Gigaom Research, bridging the gap between breaking news and long-tail research. Visit any of our reports to learn more and subscribe.

Read the original post:

IDrive’s solution to slow cloud backups: a drive shipping service